Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. ...
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company headquartered in Ashburn, Virginia, and founded in 2018 by Dr. Michael Myers and Denise Carter. The company is dedicated to addressing unmet medical needs in rare and orphan diseases, with a primary focus on dermatological conditions. Its flagship ...Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company headquartered in Ashburn, Virginia, and founded in 2018 by Dr. Michael Myers and Denise Carter. The company is dedicated to addressing unmet medical needs in rare and orphan diseases, with a primary focus on dermatological conditions. Its flagship product, QRX003, is a topical lotion being developed for Netherton Syndrome, a rare genetic skin disorder with no approved therapies. In addition, Quoin is advancing QRX004 for dystrophic epidermolysis bullosa (DEB) and QRX006 for another rare dermatological indication. The company leverages its expertise in drug delivery and formulation to create innovative topical treatments that can improve patient outcomes. As of the latest data, Quoin employs approximately 4 full-time staff, operating as a lean, virtual company. Financially, the company has no current revenue, reflecting its clinical-stage status, and reported a market cap of around $11.8 million. It has a negative enterprise value of $8.7 million, primarily due to its cash position and minimal liabilities. Key financial metrics show a current ratio of 2.868, indicating strong short-term liquidity. The company's research and development expenses have not been separately reported, but its negative operating cash flow and free cash flow underscore the high costs associated with clinical trials. Net income per share is -$5.997, and return on equity is -292.3%, illustrating substantial losses as typical for early-stage biotech. Despite these financial challenges, Quoin is led by an experienced management team, including CEO Dr. Michael Myers, who has over 38 years in the drug delivery and specialty pharma sectors, and COO Denise Carter, a co-founder. The company went public via a merger in 2021 and is listed on NASDAQ under the symbol QNRX. Quoin's mission is "to bring hope where there is currently none," focusing on patients with severe, life-altering rare diseases. The company believes its pipeline has the potential to address significant unmet medical needs and offers long-term growth opportunities if approved. As it progresses through clinical trials, Quoin aims to establish itself as a leader in rare disease therapeutics, with a commitment to innovation and patient-centric development. Future plans include advancing its pipeline, seeking partnerships, and ultimately commercializing its products to improve the lives of patients worldwide.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-15.8M
-76.3%
-9.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-13.5M
-72.3%
+34.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.61x
+1.0%
-38.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
